Hexarelin is a synthetic hexapeptide growth hormone secretagogue and one of the most potent ghrelin receptor agonists studied in laboratory research. It is notable for its strong GH-releasing activity and emerging cardiovascular research applications.
Pharmacology and GH Release
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) binds the GHS-R1a receptor with high affinity and also interacts with the CD36 scavenger receptor, a feature unique among GH secretagogue peptides. Its GH-releasing potency exceeds GHRP-6 by approximately two-fold and rivals GHRP-2, producing robust, dose-dependent increases in serum GH. The CD36 binding activity underlies hexarelin’s cardiovascular effects independent of GH secretion, making it a dual-pathway research compound. Hexarelin stimulates both GH and prolactin release, with modest cortisol elevation at higher research doses. Peak GH levels typically occur 15-30 minutes after administration in research models, with a return to baseline within 2-3 hours.
Cardiovascular Research
Hexarelin’s interaction with CD36 receptors on cardiac tissue has generated significant interest in cardiovascular research. Studies in ischemia models demonstrate reduced infarct size, improved post-ischemic recovery of left ventricular pressure, and decreased cardiomyocyte apoptosis. Hexarelin activates the PI3K/Akt survival pathway in cardiac cells, promoting protective gene expression. Research also indicates anti-atherosclerotic properties through modulation of macrophage cholesterol efflux via CD36 engagement. In pressure-overload cardiac hypertrophy models, hexarelin attenuates fibrosis and preserves systolic function. These cardiovascular effects persist even when GH receptor signaling is blocked, confirming the independent CD36-mediated mechanism. Emerging studies explore hexarelin’s potential in post-myocardial infarction remodeling and heart failure research.
Frequently Asked Questions
Why does hexarelin cause desensitization in research?
Chronic continuous hexarelin administration leads to progressive GHS-R1a receptor downregulation, reducing GH release over time. Research shows that desensitization can be mitigated through pulsatile dosing protocols with adequate inter-dose intervals. This tachyphylaxis is a class effect of GHS-R1a agonists and informs protocol design across all GHRP-type peptides.
How does hexarelin compare to ipamorelin?
Hexarelin is more potent for raw GH release but less selective, producing cortisol and prolactin elevation that ipamorelin avoids. Ipamorelin is preferred when GH-specific effects are the research endpoint, while hexarelin’s CD36 activity makes it uniquely valuable for cardiovascular research where GH-independent cardioprotection is being investigated.